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Infusion-Related Reactions With Pegloticase, a Recombinant
Uricase for the Treatment of Chronic Gout Refractory to
Conventional Therapy
Herbert S. B. Baraf, MD,* Robert A. Yood, MD,† Faith D. Ottery, MD, PhD,‡ John S. Sundy, MD, PhD,§
and Michael A. Becker, MD║
Background: In clinical trials of pegloticase, a PEGylated uricase devel-
oped for treatment of gout refractory to conventional therapy, infusion-
related reactions (IRs) were the second most frequent adverse event
reported.
Objective: The objective of this study was to provide a detailed account
of IRs with pegloticase therapy.
Methods: Data from 2 replicate, 6-month randomized trials and an
open-label extension study were pooled. Infusions of pegloticase (8 mg)
were administered biweekly or monthly; all patients received prophylaxis
(antihistamine, acetaminophen, and corticosteroid) and were tested for
urate levels prior to each infusion. An IR was defined by protocol as any
otherwise unexplained adverse event or cluster of temporally related events
occurring during or within 2 hours of infusion.
Results: Infusion-related reactions occurred in 94 (45%) of 208 patients
receiving pegloticase; 10 patients reported IRs at first infusion and 84
during subsequent infusions. Chest discomfort (15%), flushing (12%),
and dyspnea (11%) were the most common symptoms. Most IRs were
rated mild or moderate; 7% were rated severe. All IRs resolved with
slowing, interrupting, or stopping the infusion. No patient required blood
pressure or ventilatory support. Infusion-related reactions were associated
with loss of pegloticase urate-lowering efficacy: 91% of all IRs occurred
in patients with preinfusion serum uric acid concentrations (sUA) greater
than 6mg/dL. For patients sustaining preinfusion sUAof less than 6mg/dL,
IRs occurred in fewer than 1 per 100 infusions.
Conclusions: Phase 3 trial data combined with post hoc analyses dem-
onstrated that knowledge of sUA preceding each pegloticase infusion and
cessation of therapy when urate-lowering efficacy is lost provide a means
to optimize the safety of pegloticase in clinical practice.
KeyWords: pegloticase, infusion reactions, hyperuricemia, gout, uric acid,
plasma uric acid concentration
(J Clin Rheumatol 2014;20: 427–432)
P egloticase, a monomethoxypoly(ethyleneglycol)–conjugatedmammalian recombinant uricase, was developed for the treat-
ment of chronic gout refractory to existing therapies and is ap-
proved in the United States and the European Union.1 The
tolerability and efficacy of pegloticase were demonstrated in 2
replicate 6-month, randomized placebo-controlled trials (RCTs)
in patients with symptomatic gout and plasma uric acid con-
centration (pUA) of 8 mg/dL or greater who had failed or were
intolerant of allopurinol.2 Although all patients treated with
pegloticase achieved pUA of less than 6 mg/dL within 24 hours
of the first infusion, not all patients fulfilled the definition of
“responder” in these studies. “Responders” were patients who
met the primary efficacy end point defined as pUA of less than
6.0 mg/dL for 80% of the total time or greater during the third
and sixth months of treatment combined. Responder status was
achieved by 42% of patients receiving biweekly pegloticase
compared with 0% of those in the placebo group.2 Patients not
meeting the primary end point (and all patients who did not
complete the trials) were classified as “nonresponders.” Loss of
response, seen as early as 2 weeks after the first infusion, was
manifested by a preinfusion pUA of greater than 6 mg/dL. In the
pegloticase RCTs, both serum uric acid concentration (sUA) and
pUAwere measured; pUAwas used for the primary end point to
avoid possible degradation of uric acid by circulating pegloticase.
Because plasma and serum urate determinations correlated 95%
of the timewith respect tovalues greater than or less than 6mg/dL,
the more clinically accessible sUA will be described in the
remainder of this article with the exception of the protocol-
defined end points.
The primary safety concerns in the pegloticase RCTs were
gout flares, a common finding with initiation of any urate-
lowering therapy,3 and infusion-related reactions (IRs). Infusion-
related reactions were the second most common adverse event
and the most common reason for discontinuation in the RCTs.2
Furthermore, post hoc analyses of data from the RCTs revealed
relationships between urate-lowering responses to pegloticase
therapy, the development of pegloticase antibodies, and the risk
for IRs. These relationships were not appreciated while the RCTs
were in progress because investigators were blinded to uric acid
levels and the study treatments, but they provide critical insight
into factors associated with IR risk and evidence pertinent to the
prevention of IRs in clinical practice. The current report presents
detailed information on IRs occurring during the pegloticase
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trials,2,4 recommendations for managing pegloticase IRs in clin-
ical practice, and a proposed set of pegloticase stopping rules
aimed at mitigating the risk for IRs.
MATERIALS AND METHODS
Clinical Trials
Information about IRs was obtained from the replicate 6-month
RCTs (studies CO405 and CO406 or GOUT 1 and 2; identifier:
NCT00325195 2) and the subsequent open-label extension (OLE)
study data sets (C0407; identifier NCT01356498 4). The design
of the RCTs has been described previously.2 Briefly, these studies
enrolled patients with refractory gout and sUA of 8.0 mg/dL or
greater, who either had failed or had contraindications to allo-
purinol treatment, and who had at least 1 or more of the following:
3 or more self-reported gout flares over the previous 18-month
period, 1 or more tophus, or gouty arthropathy. Eligible patients
were randomized in a 2:2:1 ratio to receive 12 biweekly, 2-hour
intravenous (IV) infusions containing either pegloticase 8 mg
every 2 weeks (biweekly treatment group), pegloticase 8 mg alter-
nating with placebo at successive infusions (monthly treatment
group), or placebo. Patients were required to discontinue any pre-
trial urate-lowering therapies 1 week prior to the RCT treatment
period. Prophylaxis against gout flares with colchicine or a
nonsteroidal anti-inflammatory drug was started 1 week before
the first infusion and continued throughout the RCT. All patients
received IR prophylaxis prior to each infusion in the RCT and
OLE studies as follows: the nonsedating H1-antihistamine fex-
ofenadine, 60 mg on the night preceding and the morning of
infusion; acetaminophen, 1000 mg the morning of infusion; and
hydrocortisone, 200 mg IV given immediately prior to infusion.
Patients completing treatment in either RCTwere eligible to
enroll in the OLE study during which all patients received either
biweekly or monthly pegloticase infusions. While still blinded to
RCT treatment, the investigator and patient decided whether
pegloticase would be administered biweekly or monthly at OLE
study entry. Changes in dosing frequency from monthly to bi-
weekly or vice versa were allowed once after week 25 and a
second time after the data from the RCTs were unblinded. Flare
prophylaxis was required for the first 3 months of the OLE study
and continued at investigator discretion thereafter.
For both the RCTs andOLE study, approval of the protocolwas
obtained from central (IntegReview, Austin, TX) or local institutional
review boards, and informed consent was obtained from all patients
before any study-related procedures were performed.
The primary efficacy end point in the RCTs was the pro-
portion of responders in each treatment group achieving pUA of
less than 6.0 mg/dL for 80% of the total time or greater during
months 3 and 6 combined.2 Plasma uric acid concentration deter-
minations were completed prior to infusions and at 6 additional
times during months 3 and 6. Patients who did not meet the
pUA criteria, or who discontinued early, were classified as non-
responders. Safety assessments included physical examination
and adverse event updates every 2 weeks and laboratory testing
every month. Safety was the primary end point in the OLE;
evaluation for adverse events included physical examination at
each biweekly or monthly visit and laboratory testing performed
every 12 weeks.
Infusion-Related Reactions
Infusion-related reactions were defined in the study proto-
cols as any infusion-related adverse event or cluster of temporally
related events that occurred during or within 2 hours after drug
infusion that could not be reasonably attributed to another cause.
These events prompted a standardized assessment, which included
a thorough dermatologic and cardiopulmonary examination and
a 12-lead electrocardiogram. Vital signs were evaluated every
30 minutes until resolution or stabilization of the event. Besides
the interventions implemented by the investigator to manage the
patient’s medical condition, the infusion rate could be slowed
by half, interrupted and restarted at the same or slower rate, or
stopped. If the event resolved, the infusion could proceed to
completion at the original rate, at a reduced rate, or with increased
volume of diluent. However, the infusion was to be stopped if
the IR failed to resolve within 1 hour, or if the patient, in the
investigator’s opinion, was at risk for anaphylaxis. In the OLE,
prednisone, 20 mg on the night before the next infusion, could
be added to the prophylaxis regimen if a patient had experienced
an IR, and further pegloticase treatment was to be given.
RESULTS
Pooled Study Population
A total of 225 patients were randomized, and 212 received at
least 1 infusion of study treatment in the RCTs.2 One hundred
fifty-one (96%) of the 157 patients who completed either of the
RCTs elected to enter the OLE study (149 received pegloticase,
and 2 chose to be followed up by observation only). Overall,
208 patients received pegloticase in the 3 studies. A total of
6389 infusions were administered during the RCTs and the OLE
study (RCT biweekly, 852; monthly, 846; placebo, 502; OLE,
4189). Eighty-five patients were allocated to biweekly pegloticase
in the RCTs and received a median of 36 infusions (range, 1–63)
during combined RCT and OLE participation; 84 patients were
initially allocated to monthly pegloticase and received a median
of 23 pegloticase infusions (range, 1–57). All 39 patients random-
ized to placebo and completing 1 of the RCTs started pegloticase
in the OLE study; 23 received biweekly treatment with a median
of 20 pegloticase infusions (range, 2–51), and 16 received
monthly pegloticase with a median of 7 infusions (range, 1–26).
Overall, 91 patients (44%) received more than 30 pegloticase
infusions, and 40 patients (19%) received more than 50 infusions.
Characterization of IRs
Infusion-related reactions were reported for 94 (45%) of
208 patients treated with pegloticase during the phase 3 trials.
Two (5%) of 43 patients experienced at least 1 IR while receiving
placebo (both during the RCTs). An IR occurred during the first
pegloticase infusion in 10 (5%) of the 208 pegloticase-treated
patients and in 1 (2%) of 43 patients receiving their first placebo
infusion. Among the other 84 patients with at least 1 IR, these
events were distributed over time as shown in Figure 1. Among
patients with at least 1 IR, 93 (97%) had symptoms that arose
during the infusion, and 3 (3%) had symptoms with onset in
the 2-hour observation period after the infusion. Infusion-
related reaction was the basis for discontinuation from study
drug for 20 patients in the RCTs and for 11 patients in the
OLE study. Among these 11, 6 had received placebo in the
RCTs, and 5 were RCT nonresponders. No patient who was a
responder in the RCTs reported an IR as the basis for dis-
continuation during the OLE study.
In the pooled study population from the RCTs and OLE, the
most common symptoms defining IR (incidence >5% and
excluding IRs associated with placebo infusions) were chest
discomfort (n = 32; 15%), flushing (n = 24; 12%), dyspnea
(n = 23; 11%), back pain (n = 19; 9%), hyperhidrosis (n = 18;
9%), nausea (n = 18; 9%), erythema (n = 18; 9%), urticaria
(n = 17; 8%), chest pain (n = 17; 8%), pruritus (n = 16; 8%), rash
Baraf et al JCR: Journal of Clinical Rheumatology • Volume 20, Number 8, December 2014
428 www.jclinrheum.com © 2014 Lippincott Williams & Wilkins
(n = 13; 6%), muscle spasms (n = 13; 6%), headache (n = 12; 6%),
and abdominal pain (n = 11; 5%). Other symptoms, occurring at
rates of 2% to 5%, included dizziness (5%), vomiting (5%), pain
(4%), chills (3%), hypertension (3%), hypotension (3%), tachy-
cardia (3%), feeling hot (2%), musculoskeletal discomfort (2%),
and wheezing (2%). Most IRs were rated mild or moderate in
severity, although 12 (7%) of 169 patients who started pegloticase
during the RCTs and 11 (7%) of 149 patients who received
pegloticase in the OLE had IRs judged to be severe by the
investigator (Table 1). Of note, in patients experiencing more than
1 pegloticase-related IR, no increase in IR severity was seen over
time with treatment.
All IRs (including those classified retrospectively as ana-
phylaxis) in the RCTs and OLE study resolved with supportive
measures, which included slowing or stopping the infusion and/or
providing fluids, diphenhydramine, corticosteroids, and/or analge-
sics. Table 2 summarizes the adjustments to the infusions made
by investigators in response to IRs during phase 3 testing. As not
all reports of potential IRs were accompanied by a description of
the investigator actions, the information is presented both as a
percentage of all IRs (n = 381) and as a percentage of those IRswith
infusion adjustments recorded (n = 264). Epinephrine was admin-
istered to 3 patients: 1 for wheezing, 1 for lip swelling, and 1 for
an IR without blood pressure change. None of the patients with
IRs required intubation, mechanical ventilation, vasopressors, or
hospitalization within 2 hours after infusion, and there were no
infusion-related deaths.
IRs as Part of Symptom Clusters
A cluster or constellation of symptoms likely to be of
particular concern to clinicians was defined post hoc as the
occurrence of stridor, wheezing, perioral or lingual edema, or
hemodynamic instability with or without rash or urticaria. Twelve
(7%) of 169 patients treated with pegloticase in the RCTs
experienced such defined symptom clusters. Two patients had
IRs with a constellation of defined symptoms during the first
infusion, 3 during the second or third infusion, 5 during the fifth
infusion, and the remaining 2 during their seventh and ninth
infusions. Most IRs with a symptom constellation were moderate
in severity, except for 1 rated mild and 3 rated severe by
investigators. For 9 of these 12 patients (including the 2 affected
during the first infusion), the IR occurred when sUAwas greater
than 6 mg/dL, whereas sUA data were not available at the time
of these symptoms in 2 patients, and sUAwas less than 6 mg/dL
in the 1 remaining patient. Eighteen patients had IRs with a
constellation of defined symptoms during the OLE, including
11 patients who were initially allocated to placebo in the RCT
and started pegloticase in the OLE. In all instances, these IRs
occurred when sUAwas greater than 6 mg/dL.
Link Between IRs and Treatment Response
Pegloticase is immunogenic, and antipegloticase antibodies
were detectable in 89% of patients treated in the RCTs.2 In a post
hoc analysis, the formation of high-titer antibodies (titer exceeding
FIGURE 1. Number of first IRs with pegloticase by treatment week and sUA.














Mild 7 (8) 4 (5) 0 7 (9) 9 (13)
Moderate 11 (13) 22 (26) 2 (5) 10 (13) 23 (33)
Severe 4 (5) 8 (10) 0 7 (9) 4 (6)
aOnly the most severe episode is shown if a patient had more than 1 event; IRs were evaluated during the RCT period and again during the OLE period.
bThirty-nine of these patients entered the OLE study and were treated with pegloticase.
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1:2430) was significantly associated with loss of the urate-lowering
efficacy of pegloticase (P < 0.001).2 However, the majority of
patients with low-titer antibodies (titers <1:2430) maintained sUA
in the target range of less than 6 mg/dL. During the RCTs, most
IRs occurred when sUA levels were greater than 6 mg/dL. Retro-
spective analyses showed that the loss of urate-lowering efficacy,
as reflected by sUA of greater than 6 mg/dL, preceded a patient’s
first IR, whenever it occurred, in 20 (91%) of 22 patients treated
with biweekly pegloticase and 24 (71%) of 34 patients receiving
monthly pegloticase.2 Infusion-related reactions occurring at the
first infusion were reported for 5 patients, 1 with biweekly and 4
with the monthly pegloticase regimen. Excluding these 5 patients
(whose pUA values were >6 mg/dL by definition) shows an even
higher rate of patients with documented loss of response prior to
their first IR (95% and 80% with biweekly and monthly dosing,
respectively).
The relationship between loss of urate-lowering efficacy
and increased risk of IRs was not apparent during the conduct of
the phase 3 clinical trials because investigators and patients were
blinded to uric acid levels. Entry into the OLE study required
completion of the RCT, so that investigator’s blinding was main-
tained for many patients for several months into the OLE study.
As noted previously, 94 patients in the pooled study population
had at least 1 IR related to an infusion of pegloticase. Of these,
81 patients (86%) had sUA of greater than 6 mg/dL (including
the 10 patients who experienced an IR at their first infusion),
and 13 patients (14%) had sUA of less than 6 mg/dL at the time
of their first IR (Fig. 1). When considered on a per-infusion rather
than a per-patient basis, the rate of IRs for patients with sUA of
less than 6 mg/dL was 0.5 per 100 infusions in the RCTs and
0.8 per 100 infusions in the OLE (Fig. 2). Considering all IRs
during the studies (including multiple IRs for individual patients),
91% of those reported in the RCTs and 88% in the OLE study
occurred when sUAwas greater than 6 mg/dL.
Discontinuation of pegloticase therapy in patients who
lose urate-lowering response offers a valuable approach for
mitigating the risk of IR. Using data from the RCTs as an
example, 36 (42%) of 85 patients treated with biweekly
pegloticase achieved the primary urate-lowering end point,
and 22 (26%) of 85 patients in this dosing group had at least
1 IR.2 These results occurred in the absence of specific rules
for stopping pegloticase treatment. A post hoc analysis of the
biweekly pegloticase dosing group in the RCTs illustrated the
impact of several possible stopping rules based on sUA. As
shown in Table 3, a stopping rule based on 2 consecutive uric
acid measurements of greater than 6 mg/dL reduced the risk
of IR by nearly half (from 26% to 14%) while having little
effect on the treatment response rate (from 42% to 41%). Use
of a stopping rule based on a single sUA measurement of
greater than 6 mg/dL would have resulted in a much greater
reduction in IR risk (to 8%), but fewer patients would have
remained in the study to achieve the primary end point
(36%). Comparable changes in IR risk and response rates were
seen for stopping rules based on 1 or 2 consecutive sUA
measurements of greater than 7 mg/dL.
Serious IRs
Serious adverse events are defined by the US Food and Drug
Administration (FDA) as those that are life threatening, require
initial or prolonged hospitalization, lead to disability or permanent
damage, cause death, or jeopardize the patient such that medical
or surgical intervention is needed to prevent 1 of these outcomes.5
In the pegloticase-treated pooled population, 22 (11%) of the 208
patients had a serious IR, including 6 (7%) of 85 patients who
received biweekly pegloticase in the RCT, 9 (11%) of 84 patients
who receivedmonthly pegloticase, and 7 (18%) of 39 patients who
were initially allocated to placebo and then started pegloticase
in the OLE study. Serious IRs occurred more frequently at early
time points, with 2 episodes at the first infusion of pegloticase,
14 episodes through 6 months, and the remaining 6 episodes
occurring after 6 months. As noted above, no serious IR occurred
in the placebo groups of the RCTs. All serious IRs resolved with
supportive measures.
TABLE 2. Adjustments Made to Infusions by Investigators During the RCTs and OLE
Adjustment to Infusion Total No. of IRs No. and Percentage of Actions per Total Infusion-RelatedReactions
Infusion stopped and not restarted on day of IR All IRs 30/381 (8%)
IRs with action noted 30/246 (12%)
Infusion slowed without stopping All IRs 34/381 (9%)
IRs with action noted 34/246 (14%)
Infusion interrupted and restarted at same
or new rate
All IRs 151/381 (40%)
IRs with action noted 151/246 (63%)
Drug discontinued All IRs 31/381 (8%)
IRs with action noted 31/246 (13%)
Action not specified IRs without action noted 135/381 (35%)
FIGURE 2. Incidence of IRs per 100 infusions of pegloticase
according to sUA.
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Anaphylaxis
There was no prespecified definition of anaphylaxis in the
pegloticase study protocols, and there were no reports of ana-
phylaxis in the database from investigators who participated in
the RCTs. However, a post hoc analysis was conducted during
the FDA review process, in which the following diagnostic criteria
for anaphylaxis were used: skin or tissue mucosal involvement
and either airway compromise and/or reduced blood pressure with
or without associated symptoms, which showed a temporal rela-
tionship to the pegloticase or placebo infusion with no other iden-
tifiable cause. Using this definition, the FDA identified 14 cases
(5%) of anaphylaxis or potential anaphylaxis among the 273
patients tested in the complete phases 2 and 3 clinical develop-
ment program. Among patients treated with biweekly pegloticase
in all clinical trials irrespective of dose, 8 (7%) of 123 met the
FDA’s clinical criteria for anaphylaxis. Four of these patients were
identified by the FDA as receiving biweekly pegloticase in the
RCTs and are presented in Table 4.
An additional and independent post hoc analysis was con-
ducted using the National Institute of Allergy and Infectious
Disease/Food Allergy and Anaphylaxis Network criteria for ana-
phylaxis with an unknown allergen.6 These criteria mandate acute
onset of a reaction over minutes to several hours with involvement
of the skin, mucosal tissues, or both (eg, hives, pruritus, flushing,
or swollen lips, tongue, or uvula) and either respiratory com-
promise (eg, dyspnea, wheezing, stridor, or hypoxemia) and/or
reduced blood pressure or associated symptoms of end-organ dys-
function (eg, hypotonia, syncope, or incontinence). Applying
these criteria, 3 (4%) of 85 patients treated with biweekly
pegloticase met the National Institute of Allergy and Infectious
Disease/Food Allergy and Anaphylaxis Network clinical criteria
for anaphylaxis.2
DISCUSSION
These data from the RCTs and OLE study show that the risk
of IR with pegloticase is associated with loss of urate-lowering
efficacy as reflected by sUA of greater than 6 mg/dL. For patients
who maintain therapeutic response to pegloticase with sUA of less
than 6 mg/dL, the risk of IRs is relatively low (<1 event per 100
infusions). In comparison, the rate increases to approximately 5
events per 100 infusions in patients with sUA of greater than
6mg/dL. Similarly, the analyses of various subsets of IRs, including
those characterized by a constellation of symptoms, those meeting
the FDA definition for serious adverse events, and those suggestive
of anaphylaxis, indicated that the great majority of events occurred
in patients with preinfusion sUAmeasurement exceeding 6 mg/dL.
The loss of urate-lowering efficacy has been mechanistically
associated with the production of high-titer (>1:2430) antipegloticase
antibodies. In a post hoc analysis, only 2% of patients with antibody
titers exceeding 1:2430 maintained a urate-lowering response
to pegloticase compared with 63% of patients who were treated
for at least 2 months without developing high-titer antibodies
(P < 0.001).2,7 These findings imply that the risk of IRs may be
associated with antibody titer. Indeed, the incidence of IRs was
higher among patients who developed high-titer antibodies
compared with those who had titers that did not exceed 1:2430
(60% vs 19%; P < 0.001).2 It is, however, important to note that
antibody titers at the time of a first IR (versus the final highest
titer) were not a reliable predictor of urate response and IR risk.
The mechanism(s) underlying the development of IRs with
pegloticase remain unclear. Pegloticase induces production of
antibodies of the immunoglobulin M and immunoglobulin G
isotypes, which appear to target the polyethylene glycol moiety
rather than the uricase.8,9 In the RCTs, these antibodies did not
neutralize pegloticase activity in vitro except in 1 patient.7
TABLE 3. Stopping Rules to Evaluate Benefit (Treatment Response) Versus Risk (IRs) With Biweekly Pegloticase Based on Data Pooled
From the RCTs
Stopping Rule
Patients With IRs, n (%) Patients Continuing Treatment and Achieving Treatment Response, n (%)
Pooled RCTs (n = 85) Pooled RCTs (n = 85)
None 22 (26) 36 (42)
One sUA >6 mg/dL 7 (8) 31 (36)
One sUA >7 mg/dL 7 (8) 32 (38)
One sUA >8 mg/dL 9 (11) 33 (39)
Two consecutive sUA >6 mg/dL 12 (14) 35 (41)
Two consecutive sUA >7 mg/dL 12 (14) 35 (41)
Two consecutive sUA >8 mg/dL 13 (15) 36 (42)
TABLE 4. Summary of 4 IRs Listed in Pegloticase Label
Patient Symptoms Severity Adjudication No. of Doses Action Outcome
1 Dyspnea, tongue edema Moderate 5 Drug discontinued Resolved
Diphenhydramine 25 mg IV
2 Dyspnea, urticaria, tachycardia,
elevated blood pressure
Moderate 5 Drug discontinued Resolved
Diphenhydramine, albuterol, IV
3 Eye pruritus, periorbital edema, chest discomfort,
throat irritation, arthralgia, back pain
Mild 3 Drug discontinued Resolved
4 Flushing, pruritus, hypotension, tachycardia,
urticariaa
Mild 1 Drug discontinued Resolved
Diphenhydramine, demerol
aPatient did not take full premedication regimen.
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From a practical perspective, the risk of IR and anaphylaxis
with pegloticase therapy is likely to be reducible through routine
monitoring of sUA levels prior to each pegloticase infusion, and
then discontinuing pegloticase therapy if sUA exceeds 6 mg/dL,
particularly when 2 consecutive measurements show sUA greater
than 6 mg/dL or an IR occurs. In fact, early postapproval safety
surveillance in the United States has demonstrated a 69% reduction
in the rate of IR compared with the IR rate recorded during the
RCTs.10 The stopping rules exercise shown in Table 3 provides a
framework for appreciating the shift in risk-benefit that is possible
with preinfusion uric acid–guided treatment within the RCT
population and should be augmented in real-world practice with
clinical experience and individualized care.
All patients treated in the phase 3 studies were premedicated
with H1-antihistamines and corticosteroids and then monitored
closely for signs and symptoms of IRs during the 2-hour infusion
of pegloticase. Monitoring is recommended even if no adverse
events were observed during or after previous infusions, and
sUA testing should be done as near as is practical to each
successive infusion.
In the event of an IR, besides any interventions implemented
to manage the patient’s medical condition, the infusion rate could
be slowed by half or stopped. If the reaction resolved, then the
infusion can proceed to completion, either at the original rate, at
a reduced rate, or using an increased volume of diluent. In no
instance during the clinical trials did a second IR occur upon
restarting the infusion on the same day. However, the infusion
should be stopped and not restarted if the IR fails to resolve within
1 hour, or if the patient is believed to be at risk for an anaphylactic
reaction. If a severe or serious IR occurs, the infusion should be
stopped, and supportive treatment with antihistamines, fluids,
corticosteroids, analgesics, and/or epinephrine provided. Physician
discretion should guide further treatment if a patient experiences
an IR and their preinfusion sUA is less than 6 mg/dL. In summary,
monitoring sUA levels, stopping pegloticase if urate-lowering
treatment response is lost, and monitoring patients during infusions
are effective steps that should be taken tominimize the risk of IRs in
patients treated with pegloticase.
KEY POINTS
Monitoring preinfusion uric acid levels in patients treated
with pegloticase provides critical information on the response to
therapy and the appropriateness of continuing treatment.
Understanding the relationship between uric acid response
and IRs seen in the pegloticase clinical trials combined with
ongoing postapproval pharmacovigilance data can continue to
inform patient management and minimize IR risk.
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